# PTC Therapeutics Reports Positive Topline Results from Month 24 Interim Analysis of PIVOT-HD Extension Study of Votoplam
Canonical URL: https://biopharmsignal.com/news/PTCT/ptc-therapeutics-reports-positive-topline-results-from-month-24-interim-analysis-of-pivot-hd-extension-study-of-votoplam
Ticker: PTCT
Company: PTC Therapeutics, Inc.
Source: PTC Therapeutics, Inc.
Published: 2026-04-28 20:05 EST
Original Source URL: https://ir.ptcbio.com
## Summary

- Dose-dependent benefit on cUHDRS in Stage 2 participants compared to matched natural history cohort, with 52% slowing at 10 mg dose - - Continued evidence of favorable safety profile -  - Novartis initiated global Phase 3 INVEST-HD study of votoplam - - PTC will host a conference call to discuss

## Article Body
- Dose-dependent benefit on cUHDRS in Stage 2 participants compared to matched natural history cohort, with 52% slowing at 10 mg dose - - Continued evidence of favorable safety profile -  - Novartis initiated global Phase 3 INVEST-HD study of votoplam - - PTC will host a conference call to discuss
## Recent Company News
- 2026-05-07 20:01 EST — [PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/PTCT/ptc-therapeutics-provides-corporate-update-and-reports-first-quarter-2026-financial-results) — Source: PTC Therapeutics, Inc.
- 2026-05-04 12:00 EST — [PTC Therapeutics to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/PTCT/ptc-therapeutics-to-participate-in-upcoming-investor-conferences) — Source: PTC Therapeutics, Inc.
- 2026-04-28 20:05 EST — [PTC Therapeutics Reports Positive Topline Results from Month 24 Interim Analysis of PIVOT-HD Extension Study of Votoplam](https://biopharmsignal.com/news/PTCT/ptc-therapeutics-reports-positive-topline-results-from-month-24-interim-analysis-of-pivot-hd-extension-study-of-votoplam) — Source: PTC Therapeutics, Inc.
- 2026-04-28 13:28 EST — [PTC Therapeutics to Report Results from PIVOT-HD Long Term Extension Study](https://biopharmsignal.com/news/PTCT/ptc-therapeutics-to-report-results-from-pivot-hd-long-term-extension-study) — Source: PTC Therapeutics, Inc.
- 2026-04-22 12:00 EST — [PTC Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026](https://biopharmsignal.com/news/PTCT/ptc-therapeutics-to-report-first-quarter-2026-financial-results-on-thursday-may-7-2026) — Source: PTC Therapeutics, Inc.
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)